HER2-targeting should be considered for patients with advanced HER2-positive SGC. There are no data to guide the selection of one anti-HER2 agent over another in the palliative setting. Trastuzumab plus docetaxel can be considered for patients with a high disease burden, while trastuzumab plus pertuzumab is a good option for patients with low disease burden or borderline performance status. T-DM1 or T-Dxd can be considered upon disease progression on trastuzumab-combination therapies, although these antibody-drug conjugates can also be used upfront. Future research should investigate predictive biomarkers, the combination of HER2 and androgen blockade, and the application of novel therapies from breast cancer.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- tyrosine kinase
- cancer therapy
- small cell lung cancer
- endothelial cells
- palliative care
- risk factors
- type diabetes
- radiation therapy
- adipose tissue
- locally advanced
- machine learning
- advanced cancer
- deep learning
- electronic health record
- squamous cell carcinoma
- young adults